Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 11/20 | 0.43 |
| ▸ | NPY1R | P25929 | 6/20 | 0.43 |
| ▸ | NPY2R | P49146 | 4/20 | 0.43 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.43 |
| ▸ | FNTA | P49354 | 8/20 | 0.38 |
| ▸ | FNTB | P49356 | 8/20 | 0.38 |
| ▸ | PGGT1B | P53609 | 8/20 | 0.38 |
| ▸ | APLNR | P35414 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30390440 | 1.00 | NPY4R (0.43) | NPY4RNPY1RNPY2RNPY5RFNTA | |
| SCHEMBL30391081 | 1.00 | NPY4R (0.43) | NPY4RNPY1RNPY2RNPY5RFNTA | |
| SCHEMBL30390767 | 0.98 | NPY4R (0.46) | NPY4RNPY1RNPY2RNPY5RFNTA | |
| SCHEMBL38660264 | 0.94 | NPY4R (0.46) | NPY4RNPY1RNPY2RNPY5RFNTA | |
| SCHEMBL31453827 | 0.94 | NPY4R (0.46) | NPY4RNPY1RNPY2RNPY5RFNTA | |
| SCHEMBL30389778 | 0.94 | NPY4R (0.45) | NPY4RNPY1RNPY2RNPY5RAPLNR | |
| SCHEMBL30931482 | 0.94 | NPY4R (0.43) | NPY4RNPY1RNPY2RNPY5RAPLNR | |
| SCHEMBL31453796 | 0.93 | NPY4R (0.47) | NPY4RNPY1RNPY2RNPY5RFNTA | |
| SCHEMBL30932146 | 0.93 | NPY4R (0.42) | NPY4RNPY1RNPY2RNPY5RAPLNR | |
| SCHEMBL30513903 | 0.93 | APLNR (0.41) | NPY4RNPY1RNPY2RNPY5RFNTA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260014278-A1 | HYBRID PEPTIDE DENDRIMER SYSTEMS AND EXTRAHEPATIC DELIVERY | NUNTIUS THERAPEUTICS LTD (GB) | 2026-01-15 | — | — | US | disclosed |
| US-20250384971-A1 | METHODS FOR CHARACTERISATION OF NANOCARRIERS | NUNTIUS THERAPEUTICS LTD (GB) | 2025-12-18 | — | — | US | disclosed |
| EP-4581633-A1 | METHODS FOR CHARACTERISATION OF NANOCARRIERS | NUNTIUS THERAPEUTICS LIMITED (GB) | 2025-07-09 | — | — | EP | disclosed |
| EP-4565279-A1 | HYBRID PEPTIDE DENDRIMER SYSTEMS AND EXTRAHEPATIC DELIVERY | NUNTIUS THERAPEUTICS LIMITED (GB) | 2025-06-11 | — | — | EP | disclosed |
| WO-2024047246-A1 | METHODS FOR CHARACTERISATION OF NANOCARRIERS | NUNTIUS THERAPEUTICS LIMITED (GB) | 2024-03-07 | — | — | WO | disclosed |
| WO-2024028465-A1 | HYBRID PEPTIDE DENDRIMER SYSTEMS AND EXTRAHEPATIC DELIVERY | NUNTIUS THERAPEUTICS LIMITED (GB) | 2024-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260014278-A1 | HYBRID PEPTIDE DENDRIMER SYSTEMS AND EXTRAHEPATIC DELIVERY | CD47, CD2BP2, CD40LG | NPY4R 771/4885NPY1R 1523/4885NPY2R 1437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.